Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Estudo do Cateter VARIPULSE e do Gerador TRUPULSE com o Software VARIPULSE PRO em Participantes com PsAF (VP-EXTRA)

2 de novembro de 2026 atualizado por: Biosense Webster, Inc.

Estudo de Fluxo de Trabalho do Cateter VARIPULSE™ com o Gerador TRUPULSE™ para Tratamento de Fibrilhação Auricular Persistente (PsAF) com o Novo Software VARIPULSE™ Pro

The main purpose of this study is to investigate the workflow of the clinical use of the pulsed field (PF) ablation system (VARIPULSE catheter and TRUPULSE generator) when used for cardiac ablation with the new VARIPULSE Pro software in participants with persistent atrial fibrillation (PsAF; irregular, rapid heart rhythm that lasts over 7 days and doesn't stop on its own)

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

42

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Bad Oeynhausen, Alemanha, 32545
        • University Hospital of the Ruhr-University of Bochum
      • Aalst, Bélgica, 9300
        • AZORG campus Aalst Moorselbaan
      • Bruges, Bélgica, 8000
        • A.Z. Sint Jan
      • Aarhus N, Dinamarca, 8200
        • Aarhus University Hospital
      • San Donato Milanese, Itália, 20097
        • IRCCS Policlinico San Donato
      • Vilnius, Lituânia, 08406
        • Vilnius University Hospital Santaros Clinics

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion criteria:

  • Diagnosed with symptomatic persistent atrial fibrillation (PsAF)
  • Selected to undergo an ablation procedure for management of their arrhythmia by pulmonary vein isolation (PVI) +
  • Failed at least one antiarrhythmic drug (AAD; class I to IV) as evidenced by recurrent symptomatic atrial fibrillation (AF), or intolerable or contraindicated to the AAD
  • Age 18-75 years
  • Willing and capable of providing consent
  • Able and willing to comply with all pre-, post- and follow-up testing and requirements

Exclusion criteria:

  • Continuous AF greater than (>) 12 months (1-Year) (Longstanding Persistent AF)
  • Previous surgical or catheter ablation for atrial fibrillation
  • Any cardiac surgery within the past 2 months (60 days prior to consent date) (includes percutaneous coronary intervention [PCI])
  • Previous coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (for example, ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure
  • Any carotid stenting or endarterectomy
  • Presence of left atrium (LA) thrombus
  • Severe dilatation of the LA (left atrial diameter (LAD) > 50 millimeter [mm] antero-posterior diameter in case of transthoracic echocardiography [TTE])
  • Severely compromised left ventricular ejection fraction (LVEF less than [<] 40%)
  • Known significant pulmonary vein (PV) anomaly that in the opinion of the investigator would preclude enrollment in this study
  • Prior diagnosis of pulmonary vein stenosis
  • Pre-existing hemi diaphragmatic paralysis
  • History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  • MI within the past 2 months (60 days prior to consent date)
  • Documented thromboembolic event (including transient ischemic attack [TIA]) within the past 6 months (180 days prior to consent date)
  • Rheumatic Heart Disease
  • Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV
  • Severe mitral regurgitation
  • Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months
  • Unstable angina pectoris within the past 6 months prior to consent date
  • Acute illness or active systemic infection or sepsis
  • Previously known AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause (for example, documented obstructive sleep apnea, acute alcohol toxicity, morbid obesity (Body Mass Index >40 kilogram per meter squared [kg/m^2]), renal insufficiency (with an estimated creatinine clearance < 30 mL/min/1.73 m^2)
  • Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch, prosthetic valve or other abnormality that precludes catheter introduction or manipulation
  • Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter
  • Presence of any other condition that precludes appropriate vascular access (such as Inferior Vena Cava [IVC] filter)
  • Significant pulmonary disease, (for example, restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease [COPD]) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
  • Significant congenital anomaly or medical problems that in the opinion of the investigator would preclude enrollment in this study
  • Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation.
  • Current enrollment in an investigational study evaluating another device, biologic, or drug
  • Presenting contra-indications for the devices used in the study, as indicated in the respective instruction for use (IFU)
  • Categorized as vulnerable population and requiring special treatment with respect to safeguards of well-being
  • Life expectancy less than 12 months
  • Contraindication for MRI such as use of contrast agents due to advanced renal disease, claustrophobia, implantable pacemakers, implantable cardioverter/defibrillators (ICDs),etc. (at PI discretion)
  • Presence of iron-containing metal fragments in the body
  • Unresolved pre-existing neurological deficit

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Pulsed Field Ablation: VARIPULSE Catheter with TRUPULSE Generator and VARIPULSE Pro Software

Participants undergoing cardiac ablation for management of treatment of symptomatic Persistent Atrial Fibrillation (PsAF) will undergo pulsed field ablation (PFA) with the VARIPULSE Catheter and the TRUPULSE Generator with the new VARIPULSE Pro software.

Pulsed field ablation by VARIPULSE catheter with TRUPULSE generator along with VARIPULSE Pro software will be used.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Acute Procedural Success
Prazo: Intraoperative

Acute procedural success, which is defined as electrical isolation of clinically relevant targeted PVs (confirmed by entrance block) after adenosine/isoproterenol challenge at the end of the index ablation procedure will be reported.

Intraoperative
Pulmonary Vein Isolation (PVI) Durability
Prazo: Up to 3 months post index ablation procedure

PVI durability is defined as sustained isolation of PVs that are targeted in the index ablation procedure, which is evidenced by the confirmation of isolation via the electro-anatomical mapping 90 days (+/- 14 days) post index ablation procedure.

Up to 3 months post index ablation procedure
Pulsed Field (PF) Applications Time
Prazo: Intraoperative

PF applications time will be reported.

Intraoperative
Number of PF applications
Prazo: Intraoperative

Number of PF applications will be reported.

Intraoperative
Tissue Proximity Indication (TPI)
Prazo: Intraoperative

TPI will be reported.

Intraoperative

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Occurrence of Serious Adverse Device Effects (SADE) (Within Seven (7) days) of Index Ablation Procedure) Where the Investigational Devices were Used per Clinical Investigation Plan
Prazo: Up to 7 days post index ablation procedure

A SADE is an adverse device effect that has resulted in any of the consequences characteristic of an serious adverse event (SAE). A SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect.

Up to 7 days post index ablation procedure
Occurrence of Unanticipated Serious Adverse Device Effects (USADEs)
Prazo: Up to 3 months post index ablation procedure

An USADE is any SAE on health, safety, any life-threatening problem, or death caused by, or associated with a device, if that effect, problem, or death was not previously identified in nature, severity, outcome, or degree of incidence in the current investigational plan or risk analysis report, or any other unanticipated serious problem associated with a device that relates to rights, safety, or welfare of participants.

Up to 3 months post index ablation procedure
Occurrence of SAEs
Prazo: At 7 days, 8 to 30 days (peri-procedural) and up to 3 months post index ablation procedure

An SAE is any event that led to any of the following: Death, Serious deterioration in the health of a participant that resulted in any of the following: life-threatening illness or injury, permanent impairment of a body structure or a body function, in-patient hospitalization or prolongation of patient hospitalization, medical or surgical intervention to prevent ife-threatening illness or injury or permanent impairment to body structure or a body function, chronic disease and fetal distress, fetal death or a congenital physical or mental impairment or birth defect.

At 7 days, 8 to 30 days (peri-procedural) and up to 3 months post index ablation procedure
Occurrence of Non-Serious Adverse Events (Non-SAEs)
Prazo: Up to 3 months post index ablation procedure

An Adverse Event (AE) means any untoward medical occurrence, unintended disease or injury or any untoward clinical signs, including an abnormal laboratory finding, in participants, users or other persons, in the context of a clinical investigation, whether or not related to the investigational device.

Up to 3 months post index ablation procedure
Occurrence of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by Magnetic Resonance Imaging (MRI) Evaluations
Prazo: Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure

Occurrence of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation.

Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
Anatomical Location of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by MRI Evaluations
Prazo: Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure

Anatomical location of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation.

Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
Size of New Post-Ablation Asymptomatic and Symptomatic Cerebral Emboli Observed Post-Ablation as Determined by Magnetic Resonance Imaging (MRI) Evaluations
Prazo: Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure

Size of new post-ablation asymptomatic and symptomatic cerebral emboli will be evaluated using cerebral MRI performed post-ablation.

Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
Occurrence of New or Worsening Neurological Deficits
Prazo: Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure

Occurrence of new or worsening neurological deficits will be assessed.

Post-ablation (within 72 hours after ablation) and up to 3 months post index ablation procedure
Mini Mental State Examination (MMSE) Total Score
Prazo: Baseline (within 72 hours prior to ablation), and post-ablation (72 hours after ablation procedure)

The MMSE is a, structured examination of cognitive function. It has a total score of 30 points (0-30), and any score equal to or lower than 26 points indicates cognitive impairment.

Baseline (within 72 hours prior to ablation), and post-ablation (72 hours after ablation procedure)
National Institutes of Health Stroke Scale (NIHSS) Score
Prazo: Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)

The NIHSS is a clinician-reported measure of neurological deficit with scores ranging from 0 to 42. No stroke symptoms (0), mild stroke (1-4), moderate stroke (5-15), moderate to severe stroke (16-20), and sever (21-42).

Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)
Modified Rankin Scale (mRS) Scale Score
Prazo: Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)

The mRS score is a validated score measuring neurologic outcomes after cardio-pulmonary resuscitation (CPR) where:

  • mRS 0: No symptoms.
  • mRS 1: No significant disability. Able to perform all usual activities, despite some symptoms.
  • mRS 2: Slight disability. Independent but unable to perform usual activities (work, sports, leisure).
  • mRS 3. Moderate disability. Requires assistance, but able to walk alone.
  • mRS 4: Moderately severe disability. Walking assistance and/or daily living activities not possible.
  • mRS 5. Major disability. Bedridden, incontinent and requires constant nursing care and attention.
  • mRS 6: Death.
Baseline (within 72 hours pre ablation procedure), and post-ablation (72 hours after ablation procedure)
Occurrence of Severe Pulmonary Vein (PV) Stenosis
Prazo: Up to 3 months post index ablation procedure

Occurrence of severe PV stenosis as determined by Computed Tomography (CT)/ Magnetic Resonance Angiogram (MRA) evaluations will be reported.

Up to 3 months post index ablation procedure

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Biosense Webster, Inc. Clinical Trial, Biosense Webster, Inc.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

19 de maio de 2026

Conclusão Primária (Estimado)

30 de dezembro de 2026

Conclusão do estudo (Estimado)

30 de dezembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

19 de fevereiro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

19 de fevereiro de 2026

Primeira postagem (Real)

23 de fevereiro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • BWI202513
  • BWI202513 (Outro identificador: Biosense Webster, Inc.)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The data sharing policy of Johnson & Johnson MedTech is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Sim

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .